Pre-Emptive Use of Rituximab in Epstein-Barr Virus Reactivation: Incidence, Predictive Factors, Monitoring, and OutcomesApostolia Papalexandri, Αchilles Anagnostopoulos, Anna Vardi et al.|Blood|2020Cited by 0